Key Highlights

  • BioMarin announced the consummation of its acquisition of Amicus Therapeutics, making Amicus a wholly‑owned subsidiary.
  • The filing notes that Amicus’ independent auditor consent.
  • The amendment was submitted to the EXCHANGE COMMISSION Washington, D.C. 20549.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) disclosed that it has finalized the purchase of Amicus Therapeutics, Inc. The transaction was concluded under the terms of a merger agreement originally signed in the previous year. Following the closing, the company submitted a supplemental filing to the U.S.

Regulator to amend its earlier disclosure.

Acquisition Completion

The agreement resulted in Amicus becoming a wholly‑owned subsidiary of BioMarin, aligning with the company’s strategic aim to broaden its rare‑disease portfolio. The filing confirms that all required regulatory steps have been satisfied, and the corporate structure now reflects the new ownership arrangement.

Regulatory Filing Details

The amendment was directed to the EXCHANGE COMMISSION Washington, D.C. 20549. It replaces earlier statements that omitted certain financial metrics.

BioMarin stresses that the submission is intended solely for compliance and informational purposes, without implying any change to previously reported results.

Auditor Consent Documentation

Amicus’ independent auditor provided formal consent, which is now. This endorsement supports the accuracy of the accounting treatment applied to the transaction and underscores compliance with applicable reporting standards.

Pro Forma Financial Disclaimer

The company clarified that any pro forma financial data presented are illustrative only and should not be interpreted as reflective of the combined entity’s actual performance to date. Investors are reminded that future outcomes may differ from the illustrative scenarios. The acquisition reinforces BioMarin’s position in the rare‑disease market and expands its therapeutic reach, with management anticipating synergistic benefits as integration progresses.

In the broader biotech sector, such consolidations are common as companies seek to accelerate development timelines and enhance market presence.

Investor Impact Outlook

BioMarin indicated that the acquisition does not immediately affect its balance sheet or earnings per share. The company will continue to evaluate the combined operation’s financial outcomes and will provide subsequent disclosures to keep shareholders informed of performance metrics and integration milestones.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.